Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

$219.66
+4.55 (+2.12 %)
(As of 09/23/2019 09:21 AM ET)
Today's Range
$215.98
Now: $219.66
$220.00
50-Day Range
$209.86
MA: $217.92
$227.36
52-Week Range
$136.44
Now: $219.66
$228.19
Volume1.99 million shs
Average Volume802,815 shs
Market Capitalization$45.68 billion
P/E Ratio46.74
Dividend YieldN/A
Beta0.84
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.72 billion
Cash Flow$5.2841 per share
Book Value$15.02 per share

Profitability

Net Income$722.20 million

Miscellaneous

Employees12,800
Market Cap$45.68 billion
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences announced that its board has initiated a share buyback program on Thursday, December 7th 2017, which allows the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its earnings results on Tuesday, July, 23rd. The medical research company reported $1.38 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.33 by $0.05. The medical research company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm's quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the company posted $1.24 earnings per share. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY19 earnings guidance on Tuesday, July, 23rd. The company provided earnings per share (EPS) guidance of $5.20-5.40 for the period, compared to the Thomson Reuters consensus estimate of $5.29. The company issued revenue guidance of $4.0-4.3 billion, compared to the consensus revenue estimate of $4.16 billion.

What price target have analysts set for EW?

21 Wall Street analysts have issued 12 month price objectives for Edwards Lifesciences' shares. Their forecasts range from $120.00 to $250.00. On average, they anticipate Edwards Lifesciences' share price to reach $206.7368 in the next twelve months. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for Edwards Lifesciences.

What is the consensus analysts' recommendation for Edwards Lifesciences?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:
  • 1. According to Zacks Investment Research, "Edwards Lifesciences has reported better-than-expected second-quarter 2019 results. The company has been seeing strong TAVR sales globally. In the second quarter, it registered strong sales within Critical Care division, boosted by a surge in HemoSphere sales. With the full-market launch, the HemoSphere all-in-one monitoring platform has started to act as a major growth driver in 2019. The company is also upbeat about getting strong synergy benefit from the CASMED acquisition. Also, management looks forward to the CMS’ final update on national coverage determination related to TAVR programs. Overall, in the past three months, Edwards outperformed its industry. Meanwhile, persistent supply constraints dented Cardioband system sales. This apart, tough competition in the cardiac devices market and reimbursement issue pose concerns." (7/25/2019)
  • 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019)

Has Edwards Lifesciences been receiving favorable news coverage?

News coverage about EW stock has been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a news impact score of -1.3 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Edwards Lifesciences.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decline in short interest in August. As of August 31st, there was short interest totalling 2,116,600 shares, a decline of 6.2% from the July 31st total of 2,255,600 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.0% of the shares of the company are sold short. View Edwards Lifesciences' Current Options Chain.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Visa (V), Home Depot (HD), salesforce.com (CRM), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Netflix (NFLX) and QUALCOMM (QCOM).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.94%), BlackRock Inc. (7.94%), Vanguard Group Inc. (7.68%), Bank of New York Mellon Corp (3.28%), Jennison Associates LLC (2.90%) and Nuveen Asset Management LLC (1.90%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., BlackRock Inc., Janus Henderson Group PLC, Janus Henderson Group PLC, Wedgewood Partners Inc., Cookson Peirce & Co. Inc. and Jefferies Group LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bessemer Group Inc., Marshall Wace North America L.P., Jennison Associates LLC, Thoroughbred Financial Services LLC, Invesco Ltd., Morgan Stanley and Eaton Vance Management. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $219.66.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $45.68 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is http://www.edwards.com/.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected].


MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,093 (Vote Outperform)
Underperform Votes:  772 (Vote Underperform)
Total Votes:  1,865
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Featured Article: Bar Chart

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel